Accent Capital Management LLC purchased a new position in TuHURA Biosciences (NASDAQ:HURA – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,000 shares of the company’s stock, valued at approximately $29,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Suncoast Equity Management purchased a new stake in TuHURA Biosciences in the fourth quarter worth $421,000. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $253,000. Finally, Charles Schwab Investment Management Inc. bought a new position in TuHURA Biosciences in the fourth quarter worth approximately $61,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts have recently issued reports on HURA shares. HC Wainwright started coverage on shares of TuHURA Biosciences in a research report on Monday, March 3rd. They issued a “buy” rating and a $13.00 price objective on the stock. Rodman & Renshaw began coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th.
TuHURA Biosciences Stock Performance
NASDAQ:HURA opened at $3.53 on Friday. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93. The firm has a fifty day moving average price of $3.55.
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
- Five stocks we like better than TuHURA Biosciences
- How to Invest in the FAANG Stocks
- Affirm Strikes Back: Can a New Deal Mitigate the Recent Loss?
- Investing In Preferred Stock vs. Common Stock
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- What is the NASDAQ Stock Exchange?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
